In the latest trading session,, 0.58 million Lucid Diagnostics Inc (NASDAQ:LUCD) shares changed hands as the company’s beta touched 1.23. With the company’s most recent per share price at $1.06 changed hands at -$0.09 or -7.60% at last look, the market valuation stands at $114.96M. LUCD’s current price is a discount, trading about -69.81% off its 52-week high of $1.80. The share price had its 52-week low at $0.72, which suggests the last value was 32.08% up since then. When we look at Lucid Diagnostics Inc’s average trading volume, we note the 10-day average is 1.89 million shares, with the 3-month average coming to 1.34 million.
Analysts gave the Lucid Diagnostics Inc (LUCD) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 1 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended LUCD as a Hold, 2 felt it is a Buy and 0 rated the stock as Underweight.
Lucid Diagnostics Inc (NASDAQ:LUCD) trade information
Instantly LUCD was in red as seen in intraday trades today. With action -10.71%, the performance over the past five days has been red. The company’s shares are showing year-to-date upside of 22.28%, with the 5-day performance at -10.71% in the red. However, in the 30-day time frame, Lucid Diagnostics Inc (NASDAQ:LUCD) is -23.55% down. Looking at the short shares, we see there were 1.66 million shares sold at short interest cover period of 1.38 days.
The consensus price target for the stock as assigned by Wall Street analysts is 2, meaning bulls need an upside of 47.0% from its recent market value. According to analyst projections, LUCD’s forecast low is 2 with 2 as the target high. To hit the forecast high, the stock’s price needs a -88.68% plunge from its current level, while the stock would need to soar -88.68% for it to hit the projected low.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -54.43%. The 2025 estimates are for Lucid Diagnostics Inc earnings to increase by 31.90%, but the outlook for the next 5-year period is at 37.27% per year.
LUCD Dividends
Lucid Diagnostics Inc is expected to release its next quarterly earnings report on 2025-May-13.
Lucid Diagnostics Inc (NASDAQ:LUCD)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 34.54% of Lucid Diagnostics Inc shares while 9.78% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 14.94%. There are 9.78% institutions holding the Lucid Diagnostics Inc stock share, with LUMINUS MANAGEMENT LLC the top institutional holder. As of 2024-06-30, the company held 1.6124% of the shares, roughly 0.73 million LUCD shares worth $0.6 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 1.2461% or 0.56 million shares worth $0.46 million as of 2024-06-30.
Among Mutual Funds, the top two as of Mar 31, 2025 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . With 612.6 shares estimated at $0.65 million under it, the former controlled 0.57% of total outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held about 0.26% of the shares, roughly 276.27 shares worth around $0.29 million.
